pepaxti
oncopeptides ab - melphalan flufenamide hydrochloride - multippelt myelom - antineoplastiske midler - pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-cd38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. for patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.
hypoloc comp 5 mg / 12.5 mg
menarini international o.l. sa - nebivololhydroklorid / hydroklortiazid - tablett, filmdrasjert - 5 mg / 12.5 mg
angiox
the medicines company uk ltd - bivalirudin - akutt koronarsyndrom - antithrombotic agents - angiox er indisert som antikoagulant hos voksne pasienter som gjennomgår perkutan koronar intervensjon (pci), inkludert pasienter med st-segment-forhøyet myokardinfarkt (stemi) under primær pci. angiox er også indisert for behandling av voksne pasienter med ustabil angina / ikke-st-segment-elevation myocardial infarction (ua / nstemi) planlagt for påtrengende eller tidlig intervensjon. angiox bør administreres med acetylsalisylsyre og klopidogrel.
minirin 240 mikrog
ferring legemidler as - desmopressinacetat - smeltetablett - 240 mikrog
minirin 60 mikrog
ferring legemidler as - desmopressinacetat - smeltetablett - 60 mikrog
minirin 120 mikrog
ferring legemidler as - desmopressinacetat - smeltetablett - 120 mikrog
esidrex 25 mg
laboratoires juvisé pharmaceuticals - hydroklortiazid - tablett - 25 mg
hydrochlorothiazide orifarm 25 mg
orifarm generics (3) - hydroklortiazid - tablett - 25 mg
hydromed 12.5 mg
medilink a/s (1) - hydroklortiazid - tablett - 12.5 mg
magnesiumsulfat b. braun 1 mmol/ ml
b. braun melsungen ag - magnesiumsulfatheptahydrat - konsentrat til infusjonsvæske, oppløsning - 1 mmol/ ml